minimal Common Oncology Data Elements (mCODE) Implementation Guide
3.0.0 - STU3 Release United States of America flag

minimal Common Oncology Data Elements (mCODE) Implementation Guide, published by HL7 International / Clinical Interoperability Council. This is not an authorized publication; it is the continuous build for version 3.0.0). This version is based on the current content of https://github.com/HL7/fhir-mCODE-ig/ and changes regularly. See the Directory of published versions

: cancer-related-medication-admin-doxorubicin-jenny-m - XML Representation

Raw xml | Download



<MedicationAdministration xmlns="http://hl7.org/fhir">
  <id value="cancer-related-medication-admin-doxorubicin-jenny-m"/>
  <meta>
    <profile
             value="http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-cancer-related-medication-administration"/>
  </meta>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: MedicationAdministration</b><a name="cancer-related-medication-admin-doxorubicin-jenny-m"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource MedicationAdministration &quot;cancer-related-medication-admin-doxorubicin-jenny-m&quot; </p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-mcode-cancer-related-medication-administration.html">Cancer-Related Medication Administration Profile</a></p></div><p><b>status</b>: completed</p><p><b>category</b>: Outpatient <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.3.0/CodeSystem-medicationrequest-category.html">MedicationRequest Category Codes</a>#outpatient)</span></p><p><b>medication</b>: doxorubicin hydrochloride 20 MG per 10 ML Injection <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.3.0/CodeSystem-v3-rxNorm.html">RxNorm</a>#1790099)</span></p><p><b>subject</b>: <a href="Patient-cancer-patient-jenny-m.html">Patient/cancer-patient-jenny-m</a> &quot; M&quot;</p><p><b>effective</b>: 2018-04-22</p><h3>Performers</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Actor</b></td></tr><tr><td style="display: none">*</td><td><a href="Practitioner-us-core-practitioner-nancy-oncology-nurse.html">Practitioner/us-core-practitioner-nancy-oncology-nurse</a> &quot; NURSE&quot;</td></tr></table><p><b>reasonReference</b>: <a href="Condition-primary-cancer-condition-jenny-m.html">Condition/primary-cancer-condition-jenny-m</a></p><p><b>request</b>: <a href="MedicationRequest-cancer-related-medication-request-doxorubicin-jenny-m.html">MedicationRequest/cancer-related-medication-request-doxorubicin-jenny-m</a></p><p><b>note</b>: doxorubicin (60 mg/m² IV), 105.96 mg in 50 ml 0.9% normal saline administered by continuous infusion. Patient tolerated infusion without side effects. (By Practitioner/us-core-practitioner-nancy-oncology-nurse @2018-04-22)</p><h3>Dosages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Route</b></td><td><b>Dose</b></td></tr><tr><td style="display: none">*</td><td>Intravenous route (qualifier value) <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="https://browser.ihtsdotools.org/">SNOMED CT</a>#47625008)</span></td><td>105.96 mg<span style="background: LightGoldenRodYellow"> (Details: UCUM code mg = 'mg')</span></td></tr></table></div>
  </text>
  <status value="completed"/>
  <category>
    <coding>
      <system
              value="http://terminology.hl7.org/CodeSystem/medicationrequest-category"/>
      <code value="outpatient"/>
    </coding>
  </category>
  <medicationCodeableConcept>
    <coding>
      <system value="http://www.nlm.nih.gov/research/umls/rxnorm"/>
      <code value="1790099"/>
      <display value="doxorubicin hydrochloride 20 MG per 10 ML Injection"/>
    </coding>
  </medicationCodeableConcept>
  <subject>
    <reference value="Patient/cancer-patient-jenny-m"/>
  </subject>
  <effectiveDateTime value="2018-04-22"/>
  <performer>
    <actor>
      <reference
                 value="Practitioner/us-core-practitioner-nancy-oncology-nurse"/>
    </actor>
  </performer>
  <reasonReference>
    <reference value="Condition/primary-cancer-condition-jenny-m"/>
  </reasonReference>
  <request>
    <reference
               value="MedicationRequest/cancer-related-medication-request-doxorubicin-jenny-m"/>
  </request>
  <note>
    <authorReference>
      <reference
                 value="Practitioner/us-core-practitioner-nancy-oncology-nurse"/>
    </authorReference>
    <time value="2018-04-22"/>
    <text
          value="doxorubicin (60 mg/m² IV), 105.96 mg in 50 ml 0.9% normal saline administered by continuous infusion. Patient tolerated infusion without side effects."/>
  </note>
  <dosage>
    <route>
      <coding>
        <system value="http://snomed.info/sct"/>
        <code value="47625008"/>
        <display value="Intravenous route (qualifier value)"/>
      </coding>
    </route>
    <dose>
      <value value="105.96"/>
      <unit value="mg"/>
      <system value="http://unitsofmeasure.org"/>
      <code value="mg"/>
    </dose>
  </dosage>
</MedicationAdministration>